Three US Food and Drug Administration-approved therapies for chronic GVHD

Chronic graft-versus-host disease ( cGVHD) is a major immunologic complication of allogeneic hematopoietic cell transplantation. cGVHD involves multiple organs, reduces quality of life, and often requires prolonged therapy with glucocorticoids, causing severe side effects. After 4 decades of testing multiple therapeutic approaches, ibrutinib, belumosudil, and ruxolitinib were US Food and Drug Administration approved for cGVHD in the last 4 years. Here we put a spotlight on their mechanisms of action, studies that led to approval, and their future role in cGVHD.

Automated summary

Chronic graft-versus-host disease (cGVHD) is a major immunologic complication of allogeneic hematopoietic cell transplantation, and current treatments often have severe side effects. In recent years, ibrutinib, belumosudil, and ruxolitinib have been approved by the US Food and Drug Administration for cGVHD and hold promise for future treatment.